1. 16α-[18F]-fluoro-17β-oestradiol ([18F]FES): a biomarker for imaging oestrogen receptor expression with positron emission tomography (PET);Lefebvre-Lacoeuille;Med Nucl,2015
2. Positron tomographic assessment of estrogen receptors in breast cancer: comparison with FDG-PET and in vitro receptor assays;Dehdashti;J Nucl Med,1995
3. Positron emission tomography with 2-[18F] Fluoro-2-deoxy-D-glucose and 16alpha-[18F] fluoro-17beta-estradiol in breast cancer: correlation with estrogen receptor status and response to systemic therapy;Mortimer;Clin Cancer Res,1996
4. Positron emission tomographic assessment of “metabolic flare” to predict response of metastatic breast cancer to antiestrogen therapy;Dehdashti;Eur J Nucl Med,1999
5. Metabolic flare: indicator of hormone responsiveness in advanced breast cancer;Mortimer;J Clin Oncol,2001